Product Description
Sodium sulfide for ST-Segment Elevation Myocardial Infraction
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mallinckrodt
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Reperfusion Injury|ST Elevation Myocardial Infarction|Anesthesia Related|Atherosclerosis
Phase 1: Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00879645 |
S103 | P1 |
Terminated |
Kidney Diseases |
2010-03-01 |
2019-03-18 |
Treatments |
|
NCT00858936 |
S201 | P2 |
Terminated |
Anesthesia Related|Reperfusion Injury |
2010-04-01 |
2019-03-18 |
Treatments |
|
2009-009657-19 |
2009-009657-19 | P2 |
Terminated |
Reperfusion Injury|Atherosclerosis |
2009-12-17 |
2022-03-13 |
Treatments |
|
NCT01007461 |
IK-1001-AMI-201 | P2 |
Withdrawn |
ST Elevation Myocardial Infarction |
2009-12-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|